GlassScriptPhysician profile
Randall W Morris
NPI 1104854488
$724.93
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $14.25 · 2021: $131 · 2022: $335.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $161.82 | 2019-2022 | |
| Amgen INC. | $71.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $62.29 | 2019-2021 | |
| Lilly USA, LLC | $57.62 | 2022 | |
| Cranial Technologies, INC | $44.78 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $40.10 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.76 | 2022 | |
| Abbott Laboratories | $29.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.97 | 2019 | |
| Pfizer INC. | $25.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.61 | 2019 | |
| Corium, LLC | $18.07 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.37 | 2022 | |
| Sobi, INC | $15.36 | 2019 | |
| Tactile Systems Technology INC | $15.31 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.03 | 2021 | |
| Dexcom, INC. | $13.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.41 | 2019 | |
| Shire North American Group INC | $12.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.